

[Open Peer Review on Qeios](#)

Modotuximab

National Cancer Institute

Source

National Cancer Institute. *Modotuximab*. NCI Thesaurus. Code C152075.

A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is often overexpressed on the cell surfaces of various solid tumor cell types.